Debrecen U, AstraZeneca Sign Partnership Agreement

The University of Debrecen (DE) and the biotechnology company AstraZeneca have entered into a strategic partnership: the agreement signed on Wednesday aims, among other things, to support the early detection of diseases, strengthening appropriate diagnostic pathways, and improving patient management in areas that are considered widespread diseases in Hungary, such as cancer, cardiovascular disease and chronic respiratory diseases, according to information provided to MTI by the DE press center.

According to their announcement, the strategic agreement aims to jointly support healthcare innovations, improve patient pathway management, and increase the efficiency of patient care. The partnership covers areas such as oncology, respiratory and immunological diseases, cardiovascular and metabolic diseases and rare diseases.

As stated, programs aimed at developing data research and analysis will play a key role in the cooperation, which, based on domestic health data assets, can contribute to making patient care more transparent, sustainable, and cost-effective, thereby alleviating the ever-increasing pressure on the healthcare system.

The mission of the University of Debrecen is to build on the unity of education, research, and healing to turn the latest scientific achievements to the benefit of patients, according to a statement by Zoltán Szilvássy, rector of the University of Debrecen.

Julio Ordaz, Director of AstraZeneca's Central European Cluster, said that one of the key elements of the agreement was the further strengthening of clinical research programs and the implementation of data-driven projects based on real patient pathways, which contribute to earlier detection, more personalized therapeutic decisions, and more efficient care organization.

The common goal of the University of Debrecen and AstraZeneca is to support Hungarian healthcare with research results that can be used in everyday clinical practice, support Hungarian healthcare with research results that can be used in everyday clinical practice, whether it be reducing the time it takes to make a diagnosis or making more accurate therapeutic decisions, which can contribute to improving patients' quality of life and making healthcare more sustainable in the long term, they wrote in the announcement.